eighth meeting parties decided dec viii note appreciation work done technology economic assessment panel technical options committee pursuant decision iv fourth meeting parties decision vii seventh meeting parties note appreciation one new non cfc based mdi one active ingredient entered market countries others anticipated next one three years non cfc treatments devices already provide suitable alternative many patients parties operating article request parties operating article developed national transition strategy report panel relevant technical options committee details national transition strategy non cfc treatments asthma chronic obstructive pulmonary disease time meetings technical options committee beginning request technology economic assessment panel relevant technical options committee provide interim report progress development implementation national transition strategies parties operating article non cfc treatments asthma chronic obstructive pulmonary disease copd report open ended working group preparation ninth meeting parties request technology economic assessment panel examine provide progress report ninth meeting parties final report tenth meeting parties issues surrounding transition non cfc treatments asthma chronic obstructive pulmonary disease parties operating article fully protective public health doing technology economic assessment panel consult international bodies world health organization institutions representing health care professionals patient advocacy groups private industry national bodies governments technology economic assessment panel consider context transition phase decisions taken within montreal protocol framework national strategies might complement other impact right ability patients parties operating article countries economies transition parties operating article large disadvantaged communities importing countries receive cfc based mdis medically acceptable affordable alternatives available due reductions essential use exemptions parties operating article cfc based mdis influence potential transferable essential use exemptions well existing potential trade restrictions individual countries smooth transition access affordable treatment options international markets fluidity trade cfc based mdis well alternative treatments asthma chronic obstructive pulmonary disease implications patient subgroups may continuing compelling medical needs virtual phase out range regulatory non regulatory incentives for impediments to research development alternative treatments asthma chronic obstructive pulmonary disease market penetration alternative treatments asthma chronic obstructive pulmonary disease degree dry powder inhalers dpis treatment options may considered medically acceptable affordable alternatives cfc based mdis consultation bodies result factors may influence ability act substitutes different countries relative implications phase out ozone depleting substances different policy options facilitate transition non cfc treatments steps could taken facilitate access affordable non cfc treatment options technology